CureVac

CureVac is a biopharmaceutical company specializing in the prophylactic and therapeutic application of messenger RNA.

CureVac GmbH is a biopharmaceutical company specializing in the prophylactic and therapeutic application of messenger RNA (mRNA). CureVac's lead programme is dedicated to the development of active immunotherapies (based on its RNActive technology) for the treatment of prostate cancer and non-small cell lung cancer. Furthermore, in preclinical studies, CureVac is developing prophylactic vaccines and adjuvants to address infectious diseases.